Status
Conditions
Treatments
About
The objectives of this study are to confirm the early to mid-term safety, performance, and clinical benefits of the Z1 Femoral Hip System in hemi-hip arthroplasty and primary total hip arthroplasty.
The primary objective of this post market clinical follow-up (PMCF) study is the assessment of safety by recording and analyzing the survival of the implant system at 2 years post-implantation. Safety will also be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to implant, instrumentation, and/or procedure should be specified.
The secondary objective is the assessment of functional performance and clinical benefits of the Z1 Femoral Hip System demonstrated by recording patient-reported clinical outcomes measures (PROMs).
Full description
Total hip arthroplasty (THA) is a common operative treatment where an arthritic, degenerative or fractured hip joint is replaced with a prosthetic device if conservative options are unable to relief pain and debilitating symptoms. A femoral stem component is used in conjunction with a femoral head component for the replacement of the proximal femur in total hip or hemi hip arthroplasty. THA now includes young and active patients, as well as very old ones thanks to the continuous improvement in implant design. Major indications include osteoarthritis, rheumatoid arthritis, avascular necrosis (AVN) and hip fractures. The surgical procedure consists in replacing the head of the femur and acetabulum (socket) with a prosthesis. Another type of hip arthroplasty is called Hemi arthroplasty, which does not include the replacement of the acetabulum.
This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum. Device components are made from durable materials that can withstand loads applied to the artificial hip joint during physical activity, are resistant to corrosion and fatigue, provide minimal friction and wear, and are biocompatible. Commonly used materials include cobalt chrome, commercially pure titanium, titanium alloy with aluminum and vanadium, ceramics, and ultrahigh molecular weight polyethylene.
Clinical studies have proven implant longevity in both cementless and cemented THA, offering patients effective long-term relief. In cementless THA, successful biological fixation is dependent on bony on-growth onto the surface of the prosthesis whereas, cemented fixation depends on a stable interface between prosthesis and cement and a solid mechanical bond between cement and bone. Ultimately, the goal of a THA is to bring the patients back to their normal routine without pain and stiffness. THA and hemiarthroplasty are both very successful procedures with an 84-97% patient satisfaction rate and an implant survival of over 90% after 10 years (THA) and implant survival of approximately 93% at 10 years (Hemiarthroplasty).
The Z1 Femoral Hip System consists of femoral hip stems intended for use in total or hemi hip arthroplasty. The triple-tapered stem is designed for implantation into the proximal femur and mates with compatible femoral heads and adapters for use in total or hemi hip arthroplasty through a 12/14 male taper connection.
The stems are manufactured from a forged titanium alloy Ti-6Al-4V and have a wedge-shaped design, with a proximal-to-distal taper. Apart from the highly polished femoral neck region, the entire surface of the stem is gritblasted and sprayed with a Ti-6Al-4V titanium alloy plasma coating followed by a hydroxyapatite (HA) overcoat. Offered in multiple sizes and neck lengths, the stems are available in Standard, High Offset, and Coxa Vara offsets to accommodate various patient anatomies. The hip stems are provided sterile and are for single use only. System-specific instrumentation is available to prepare the femur for implantation of the Z1 Hip System femoral stems. The Z1 Hip System is for use only with the Zimmer Biomet femoral heads and adapters, bipolar heads, and acetabular shells and liners identified in the package insert as compatible components.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patient is at least 18 years old and skeletally mature
Patient is physically and mentally willing and able, in the Investigator's opinion at the time of enrollment, to be compliant with the protocol, including all scheduled study evaluations
Patient, or the patient's legally authorized representative, is willing and able to participate in the Informed Consent process and provide their consent
Independent of study participation, patient is a candidate and qualifies for primary total hip or hemi-arthroplasty based on physical exam and medical history including at least one of the following:
Exclusion criteria
Revision arthroplasty
Acute, chronic, local, or systemic infection(s)
Severe muscular, neural, or vascular diseases that endanger the limb(s) involved
Lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible
Total or partial absence of the muscular or ligamentous apparatus
Any concomitant diseases that can jeopardize the functioning and the success of the implant
Allergy to the implanted material, especially to metal (e.g. cobalt, chromium, nickel, etc.)
Local bone tumors and/or cysts
Patient has any condition that would, in the Investigator's opinion, place the patient at undue risk or interfere with the study
Any vulnerable subject:
150 participants in 1 patient group
Loading...
Central trial contact
Taylor Rowe; Lynsey Boyle
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal